New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 5, 2014
08:36 EDTPTCTPTC Therapeutics named a new top pick at Credit Suisse
Credit Suisse said PTC Therapeutics is a new top pick following the recent CHMP recommendation. The firm expects PTC to launch Translarna in the EU in 2H and and views it as a potential billion-dollar drug. Shares are Outperform rated with a $40 price target.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
06:40 EDTPTCTPTC Therapeutics selloff yesterday unjustified, says Deutsche Bank
Subscribe for More Information
May 5, 2015
10:04 EDTPTCTOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:27 EDTPTCTPTC Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
May 4, 2015
16:23 EDTPTCTPTC Therapeutics says Translarna launch preparations underway in U.S.
PTC's lead product, Translarna, received marketing authorization in the EU in August 2014 for the treatment of nonsense mutation Duchene muscular dystrophy. As of April 30, PTC has 82 DMD patients on commercial therapy through either reimbursed early access programs or commercial sales. The U.S. commercial launch preparations are underway. In December 2014, PTC began submitting a rolling New Drug Application to the FDA for the approval of Translarna in nonsense mutation DMD. Top-line data from the company's ongoing Phase 3 ACT DMD trial is expected in the fourth quarter of this year which should form the basis for finalizing the NDA submission. Concurrently, PTC has begun building out its US commercial team and infrastructure in preparation for a potential US launch in the first half of 2016. Most recently, PTC announced the hiring of Eric Pauwels as head of commercial operations in the Americas. PTC initiated its global confirmatory Phase 3 ACT CF trial in nonsense mutation cystic fibrosis patients in June 2014. The trial is being conducted at approximately 90 clinical sites globally and is expected to enroll approximately 208 patients by the end of 2015. PTC intends to file for approval of Translarna for the treatment of nonsense mutation cystic fibrosis in the EU in the second half of 2015.
16:21 EDTPTCTPTC Therapeutics reports Q1 EPS ($1.15), consensus ($1.20)
Reports Q1 revenue $7.48M, consensus $2.97M. Cash, cash equivalents, and marketable securities totaled $280.5M at March 31, compared to $315.2M at December 31, 2014.
April 29, 2015
09:39 EDTPTCTHouse Financial Services Committee to hold a hearing
Subscribe for More Information
April 28, 2015
08:03 EDTPTCTPTC Therapeutics announces program targeting BMI1 enters Phase 1 study
Subscribe for More Information
April 23, 2015
09:18 EDTPTCTOn The Fly: Pre-market Movers
Subscribe for More Information
07:51 EDTPTCTPTC Therapeutics price target raised to $155 from $135 at Oppenheimer
Oppenheimer increased its price target on PTC after the company, along with Roche (RHHBY), presented data on its RG7800 drug that the firm believes showed proof-of-mechanism in health subjects. The firm recommends owning PTC ahead of two events: the scheduled October 2015 P3 read-out of Translarna in DMD, and an update on the MOONFISH trial of RG7800 slated to occur in early 2016. The firm keeps an Outperform rating on the shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use